Optimistic Outlook for Liquidia Technologies: Anticipated Yutrepia Launch and Strategic Growth
Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Liquidia Technologies (LQDA – Research Report).
Science Daily6 小时
An advance toward inhalable mRNA medications, vaccines
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...
来自MSN6 小时
Liquidia Corporation (NASDAQ:LQDA) Q3 2024 Earnings Call Transcript
This is not a decision we took lightly. And I note that we did not previously challenged the FDA's prior award of new ...
News Medical on MSN6 小时
Researchers make progress toward inhalable mRNA medicines
Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled.